Arlington Trust Co LLC Has $113,000 Stake in CVS Health Corporation $CVS

Arlington Trust Co LLC boosted its holdings in shares of CVS Health Corporation (NYSE:CVS) by 447.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,642 shares of the pharmacy operator’s stock after purchasing an additional 1,342 shares during the period. Arlington Trust Co LLC’s holdings in CVS Health were worth $113,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Atlas Brown Inc. increased its holdings in CVS Health by 7.6% during the 2nd quarter. Atlas Brown Inc. now owns 5,263 shares of the pharmacy operator’s stock valued at $363,000 after purchasing an additional 370 shares in the last quarter. Persium Advisors LLC boosted its position in CVS Health by 9.5% in the 2nd quarter. Persium Advisors LLC now owns 9,010 shares of the pharmacy operator’s stock valued at $622,000 after buying an additional 785 shares during the last quarter. Livelsberger Financial Advisory bought a new position in CVS Health in the 2nd quarter valued at $35,000. Peak Financial Advisors LLC bought a new position in CVS Health in the 2nd quarter valued at $1,022,000. Finally, Roxbury Financial LLC boosted its position in CVS Health by 78.3% in the 2nd quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator’s stock valued at $32,000 after buying an additional 202 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the sale, the director owned 22,156 shares in the company, valued at $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.22% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CVS shares. Jefferies Financial Group raised their price target on CVS Health from $74.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, June 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $78.00 price target on shares of CVS Health in a research report on Tuesday, August 26th. Wall Street Zen lowered CVS Health from a “buy” rating to a “hold” rating in a research report on Saturday. Barclays raised their price target on CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research report on Thursday, September 4th. Finally, Robert W. Baird upgraded CVS Health from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $71.00 to $82.00 in a report on Thursday, August 14th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.89.

CVS Health Price Performance

NYSE:CVS opened at $75.00 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. The stock’s 50-day simple moving average is $67.11 and its 200 day simple moving average is $66.33. The company has a market cap of $95.12 billion, a P/E ratio of 20.95, a P/E/G ratio of 0.83 and a beta of 0.62. CVS Health Corporation has a 52-week low of $43.56 and a 52-week high of $75.55.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.35. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business had revenue of $98.92 billion for the quarter, compared to the consensus estimate of $94.87 billion. During the same quarter in the previous year, the business earned $1.83 earnings per share. CVS Health’s quarterly revenue was up 8.4% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Tuesday, July 22nd were issued a dividend of $0.665 per share. The ex-dividend date was Tuesday, July 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.5%. CVS Health’s dividend payout ratio (DPR) is presently 74.30%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.